News & Updates

Show Multimedia Only

Remotely delivered weight-loss intervention works in breast cancer patients with high BMI

04 Sep 2025

A weight-loss intervention delivered remotely helps breast cancer patients with overweight and obesity shed some of their body weight, regardless of demographic and tumour factors, according to a secondary analysis of a phase III trial.

Remotely delivered weight-loss intervention works in breast cancer patients with high BMI

04 Sep 2025

Quitting smoking may help recovery from substance use disorders

04 Sep 2025 by

Smoking cessation is associated with sustained recovery from substance use disorders (SUDs), according to a longitudinal cohort study funded by the US National Institutes of Health (NIH).

Quitting smoking may help recovery from substance use disorders

04 Sep 2025

GLP1-RAs help fight cancers in adults with overweight, obesity

03 Sep 2025 by

New research indicates that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may confer a protective effect against cancers in adults with overweight or obesity regardless of type 2 diabetes status.

GLP1-RAs help fight cancers in adults with overweight, obesity

03 Sep 2025

Handgrip strength may help lower mortality risk in older adults with severe obesity

03 Sep 2025

Handgrip strength is predictive of all-cause mortality risk in older adults with severe obesity, and this association points to some useful thresholds for reducing the risk of death, suggest the results of a multi-country cohort study.

Handgrip strength may help lower mortality risk in older adults with severe obesity

03 Sep 2025

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

03 Sep 2025 by

The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

03 Sep 2025

Does telehealth prescribing raise risk of substance use disorder?

03 Sep 2025

Receiving a stimulant prescription for attention deficit hyperactivity disorder (ADHD) via telehealth shows no significant impact on the risk for substance use disorder (SUD) but appears to elevate the risk of subsequent stimulant use disorder (stimUD), suggests a study.

Does telehealth prescribing raise risk of substance use disorder?

03 Sep 2025

Ileostomy reversal after rectal cancer surgery: Does timing matter?

03 Sep 2025 by

In a systematic review and meta-analysis evaluating surgical outcomes in low rectal cancer patients who underwent early vs late ileostomy reversal, the former appears to be less beneficial than the latter in terms of surgical complications.

Ileostomy reversal after rectal cancer surgery: Does timing matter?

03 Sep 2025

Antipsychotic drugs tied to glucose homeostasis disruption

03 Sep 2025

Treatment with antipsychotics may lead to a significant glucose homeostasis dysregulation, regardless of exposure time, dose, diagnosis, and weight gain propensity, according to systematic review and meta-analysis.

Antipsychotic drugs tied to glucose homeostasis disruption

03 Sep 2025

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Patients with type 2 diabetes mellitus (T2DM) who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have lower odds of peptic ulcer disease when compared with insulin users, as shown in a retrospective study.

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025 by

Combination treatment with the oral, highly selective FGFR4 inhibitor irpagratinib plus atezolizumab has shown promising efficacy in patients with untreated or immune checkpoint inhibitor (ICI)-exposed hepatocellular carcinoma (HCC) with fibroblast growth factor 19 overexpression (FGF19+), while being safe and well tolerated, according to the updated results of the phase II ABSK-011-201 study.

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Remotely delivered weight-loss intervention works in breast cancer patients with high BMI

Remotely delivered weight-loss intervention works in breast cancer patients with high BMI

Quitting smoking may help recovery from substance use disorders

Quitting smoking may help recovery from substance use disorders

GLP1-RAs help fight cancers in adults with overweight, obesity

GLP1-RAs help fight cancers in adults with overweight, obesity

Handgrip strength may help lower mortality risk in older adults with severe obesity

Handgrip strength may help lower mortality risk in older adults with severe obesity

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

Does telehealth prescribing raise risk of substance use disorder?

Does telehealth prescribing raise risk of substance use disorder?

Ileostomy reversal after rectal cancer surgery: Does timing matter?

Ileostomy reversal after rectal cancer surgery: Does timing matter?

Antipsychotic drugs tied to glucose homeostasis disruption

Antipsychotic drugs tied to glucose homeostasis disruption

GLP-1 RA use in T2DM may protect against peptic ulcer disease

GLP-1 RA use in T2DM may protect against peptic ulcer disease

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

Irpagratinib plus atezolizumab combo active against FGF19+ HCC